Log in
LON:SLN

Silence Therapeutics plc (SLN.L) Share Forecast, Price & News

GBX 418
+7.00 (+1.70 %)
(As of 11/27/2020 04:35 PM ET)
Add
Compare
Today's Range
410
Now: GBX 418▼
444
50-Day Range
339
MA: GBX 404.52▼
455
52-Week Range
298
Now: GBX 418▼
646.50
Volume23,450 shs
Average Volume148,791 shs
Market Capitalization£346.65 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Read More
Silence Therapeutics plc (SLN.L) logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.55 out of 5 stars


Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:SLN
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.silence-therapeutics.com
Phone+44-20-34576900
Employees46

Debt

Debt-to-Equity Ratio0.05
Current Ratio9.82
Quick Ratio9.60

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales£1.39 million
Price / Sales249.39
Cash FlowGBX 60.37 per share
Price / Cash Flow6.92
Book ValueGBX 33.40 per share
Price / Book12.51

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares82,931,296
Market Cap£346.65 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 418
+7.00 (+1.70 %)
(As of 11/27/2020 04:35 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SLN News and Ratings via Email

Sign-up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Silence Therapeutics plc (SLN.L) (LON:SLN) Frequently Asked Questions

How has Silence Therapeutics plc (SLN.L)'s stock price been impacted by Coronavirus?

Silence Therapeutics plc (SLN.L)'s stock was trading at GBX 470 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SLN shares have decreased by 11.1% and is now trading at GBX 418.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Silence Therapeutics plc (SLN.L)?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics plc (SLN.L) in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Silence Therapeutics plc (SLN.L).

What stocks does MarketBeat like better than Silence Therapeutics plc (SLN.L)?

Wall Street analysts have given Silence Therapeutics plc (SLN.L) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Silence Therapeutics plc (SLN.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Silence Therapeutics plc (SLN.L)'s earnings last quarter?

Silence Therapeutics plc (SLN.L) (LON:SLN) posted its earnings results on Monday, September, 14th. The company reported ($13.70) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($21.70) by $8.00.
View Silence Therapeutics plc (SLN.L)'s earnings history.

What price target have analysts set for SLN?

1 analysts have issued 12-month target prices for Silence Therapeutics plc (SLN.L)'s stock. Their forecasts range from GBX 605 to GBX 605. On average, they anticipate Silence Therapeutics plc (SLN.L)'s stock price to reach GBX 605 in the next year. This suggests a possible upside of 44.7% from the stock's current price.
View analysts' price targets for Silence Therapeutics plc (SLN.L).

Who are some of Silence Therapeutics plc (SLN.L)'s key competitors?

Some companies that are related to Silence Therapeutics plc (SLN.L) include Concordia International Corp. (CXR.TO) (CXR), Travere Therapeutics (TVTX), Annexon (ANNX), Spruce Biosciences (SPRB), SQZ Biotechnologies (SQZ), PureTech Health (PRTC), Aptose Biosciences (APS), Oxford Biomedica plc (OXB.L) (OXB), Inozyme Pharma (INZY), Oncorus (ONCR), SIGA Technologies (SIGA), Biotest Aktiengesellschaft (BIO.F) (BIO), CEL-SCI (CVM), Inventiva (IVA) and Humanigen (HGEN).
View all competitors.

What other stocks do shareholders of Silence Therapeutics plc (SLN.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics plc (SLN.L) investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources Limited (ARS.L) (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), Anchiano Therapeutics (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software Holdings PLC (ALFA.L) (ALFA).

Who are Silence Therapeutics plc (SLN.L)'s key executives?

Silence Therapeutics plc (SLN.L)'s management team includes the following people:
  • Mr. Mark Andrew Rothera, Pres, CEO & Director (Age 57)
  • Dr. Rob Quinn Ph.D., CFO & Company Sec. (Age 37)
  • Ms. Gem Gokmen Hopkins, Head of IR & Corp. Communications
  • Dr. Barbara A. Ruskin, Sr. VP, Gen. Counsel & Chief Patent Officer (Age 60)
  • Ms. Linnea Elrington, VP & Head of HR
  • Dr. Giles V. Campion M.D., Head of R&D, Chief Medical Officer and Exec. Director (Age 66)
  • Dr. John Strafford, VP & Head of Bus. Devel.
  • Mr. Jørgen Wittendorff, Sr. VP & Head of Manufacturing
  • Dr. Eric Floyd, Sr. VP & Head of Global Regulatory Affairs (Age 57)

What is Silence Therapeutics plc (SLN.L)'s stock symbol?

Silence Therapeutics plc (SLN.L) trades on the London Stock Exchange (LON) under the ticker symbol "SLN."

How do I buy shares of Silence Therapeutics plc (SLN.L)?

Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Silence Therapeutics plc (SLN.L)'s stock price today?

One share of SLN stock can currently be purchased for approximately GBX 418.

How big of a company is Silence Therapeutics plc (SLN.L)?

Silence Therapeutics plc (SLN.L) has a market capitalization of £346.65 million and generates £1.39 million in revenue each year. Silence Therapeutics plc (SLN.L) employs 46 workers across the globe.

What is Silence Therapeutics plc (SLN.L)'s official website?

The official website for Silence Therapeutics plc (SLN.L) is www.silence-therapeutics.com.

How can I contact Silence Therapeutics plc (SLN.L)?

Silence Therapeutics plc (SLN.L)'s mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.

This page was last updated on 11/28/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.